CTOs on the Move


 
Restructured under new ownership in 2015, TranS1 has emerged stronger than ever – ready to support a product line that provides a foundation for living well, driven by surgeon innovation. Our impressive team includes experienced R&D, Sales and Professional Education professionals. The TranS1 team is focused on resilient and continuous training of its sales force and physician customers, employing best in class training methods that ultimately benefit patients.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.trans1.com
  • 1518 Blake Street
    Denver, CO USA 80202
  • Phone: 888.659.6630

Executives

Name Title Contact Details

Similar Companies

Tech-Med Services

Tech-Med Services is a Hauppauge, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Responselink

Responselink is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Teleflex

Teleflex is a global provider of medical devices used in critical care and surgery. We serve healthcare providers with specialty devices for vascular access, general and regional anesthesia, urology, respiratory care, cardiac care and surgery.

Healthy Heart Sleep Programs

Healthy Heart Sleep Programs is a Brockton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NeuroOne Incorporated

NeuroOne Medical Technologies Incorporated (Ticker: NMTC) is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, initially targeting epilepsy. Today, our attention is on the development and commercialization of patented thin-film, cortical electrode technology for intracranial electroencephalography (iEEG) and depth electrodes for stereoelectroencephalography (sEEG) recording of brain activity. The products currently available in these categories have significant limitations such as low recording resolution and high risk of infection. NeuroOne believes our technology can address these unmet needs upon initial commercialization with pipeline technology to advance the field by enabling minimally invasive techniques and all-in-one diagnostic and therapeutic options. While our initial focus is Epilepsy, future applications in Parkinson`s disease, Essential tremors, and Dystonia are within sight. NeuroOne technologies will be presented to a well-defined market, eager for the advancement they bring. There are 188 hospital centers licensed to perform epilepsy surgical procedures in the U.S. The current addressable market opportunity for is approximately $525.6 million. As more patients choose the minimally invasive procedures made available by NeuroOne technology, the future opportunity is estimated to be approximately $14.9 billion with full market penetration.